Clinical Trial Update: A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD [Phase 3]

View source ↗

Summary

Phase 3 study evaluating 36-week refill exchanges of Port Delivery System delivering ranibizumab for neovascular age-related macular degeneration; currently rec…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Age-related Macular Degeneration

Drugs mentioned

• Lucentis (ranibizumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Neovascular Age-related Macular Degeneration | Phase 3 | Status: RECRUITING